Glenn Batchelder ’83 was co-founder and CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. The company’s lead therapeutic program was for treating Parkinson’s disease utilizing their ARCUS® proprietary pulmonary delivery platform which delivers precise dosages with a breath-activated device. Batchelder is currently founding a new company focused on improved therapies for palliative care.
Prior to co-founding Civitas, he was the founding CEO and first employee of BIND Therapeutics (NASDAQ: BIND), a leading nanotherapeutic company. Before BIND, Batchelder was CEO of Acceleron Pharma (NASDAQ: XLRN), building the company from a research start-up to a clinical stage company with a robust preclinical pipeline and a rare blood disorder therapy in the clinic that is about to enter Phase 3 trials. Prior to Acceleron, Batchelder was Senior Vice President of Operations at Millennium Pharmaceuticals where he played an integral leadership role in the launch of VELCADE®, a breakthrough therapy for treating multiple myeloma, and was responsible for the commercial supply chain and technical operations for INTEGRILIN®.
Before entering the biotechnology field, Batchelder spent over 13 years as an executive in the environmental industry for Groundwater Technology, subsequently renamed Fluor Daniel GTI, with roles ranging from Vice President of Engineering to Vice President of World Wide Sales and Marketing. Batchelder received a B.S. in chemical engineering from Lehigh in 1983. He currently serves as the Chairman of the Board for the Massachusetts Biotechnology Council (MassBio) and a board member of the Michael J. Fox Foundation and The Possible Project.